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Maine AIDS Care 
Maine Medical Center's AIDS Consultation Service Summer 1994 
Nutrition & HIV 
From the earliest descriptions of 
AIDS in the United States, weight loss 
has been an initial complaint of a 
significant number of HIV-infected 
persons. In 1987, the CDC included 
HIV wasting syndrome as an indicator 
disease of AIDS in the revised 
surveillance case definition. Prospective 
and retrospective investigations have 
shown that 91 % to 100% of people with 
AIDS lose weight. In a report published 
in 1990, the Federation of American 
Societies for Experimental Biology 
(F ASEB) concluded that wasting and 
malnutrition were common occurrences 
in HIV disease; however, the extent of 
specific nutrient deficiencies was unclear 
and continues to be researched 1• 
Decrease in body weight, percent body 
fat, and body mass index have been 
observed in patients in the early stages 
of infection2• 
The development of malnutrition 
in patients with HIV infection is 
multifactorial and is thought to be an 
interplay between a decrease or 
alteration of food intake, malabsorption 
of ingested nutrients, and altered body 
metabolism characteristic of the disease 
process 1• 
Factors contributing to reduced 
food intake include anorexia, oral or 
esophageal lesions, nausea and vomiting, 
diarrhea, and neurologic or psychologic 
complications3 • Additional factors 
related to reduced food intake may also 
include the presence and severity of 
fatigue and it's impact on the patient's 
ability to obtain and prepare food; lack 
of money to buy food; lack of 
knowledge or interest in nutrition and 
HIV disease; and side effects of 
medications 1• 
related to small intestine injury, but 
disease of other digestive organs (ie. 
stomach, liver, pancreas) contribute as 
well. Researchers have identified three 
categories of intestinal disease: primary 
HIV infection of the enterocytes, 
secondary involvement from systemic or 
otherwise disseminated disorders (ie. 
MAI, etc.), and a syndrome of 
inflammatory bowel disease that may be 
related to an identifiable pathogen or 
cancer. Patients with malabsorption do 
not increase intake sufficiently to 
compensate for lost calories. Systemic 
infections can also contribute to anorexia 
due to cytokine-mediated inhibition of 
appetite1 • 
Persons with clinically stable 
HIV disease conserve lean body mass 
even with losses of body weight caused 
by decreased intake or malabsorption. 
However, patients with AIDS who have 
active disease, such as an opportunistic 
infection with fever, commonly are 
hypermetabolic and burn excessive 
calories, resulting in wasting. One 
research study reported metabolic 
rates 20-60 % above predicted levels 
in HIV infected persons with acute 
systemic illness or with chronic 
infection. Another study reported 
that even in the absence of acute 
illness, persons infected with HIV 
had high rates of resting energy 
expenditure (REE) resulting in 
weight loss1• 
Kotler and colleagues studied 
the impact of malnutrition on 
survival of persons with AIDS and 
found that death from wasting in 
AIDS is related to the magnitude of 
tissue depletion and is independent of 
the underlying cause of wasting. 
Nutritional malabsorption is Nutrition & HIV Cont. on pg. 2 
Stavudine (D4T) 
Approved by FDA 
Stavudine (Zerit), a new 
reverse transcriptase inhibitor, has 
been approved by the FDA for 
treatment of HIV+ patients who can 
not tolerate or are not benefiting 
from other approved therapies (ie. 
AZT, DDI, DDC). It is not 
approved for use in combination 
antiretroviral therapy. The efficacy 
of Stavudine relative to other 
available antiretrovirals is still not 
clearly established. It is generally 
well tolerated, although 15-20% of 
patients may develop peripheral 
neuropathy which is usually 
reversible with discontinuation of the 
drug. The approved dose is 40 mg 
bid at a cost of approximately 
$186.00 for 60 capsules. Bristol 
Meyers Squibb Co. the 
manufacturer, will provide the drug 
to patients who can not afford it 
through an assistance program. For 
more information call Bristol-Meyers 
Squibb at 1-800-788-0213. 




Monday - Friday 9:00 - 4:30 
Entera/, vs. Parenteral, 
Nutrition in HIV 
For patients with severe 
malnutrition, recent research has shown 
that enteral nutrition is preferable to 
parenteral nutrition in that enteral 
nutrition appears to preserve the gut 
function and maintain gut integrity. 
However, studies addressing the efficacy 
of enteral support in HIV+ patients 
remain scant. Lowfat, elemental 
formulas seem to work better with 
diarrhea and malabsorption syndromes. 
Parenteral nutrition may be 
indicated for patients who demonstrate 
intolerance to enteral feedings, have 
bowel obstruction, sever pancreatitis, 
copious/high volume diarrhea, 
intractable vomiting, or in malnourished 
patients who require prolonged bowel 
rest. It should not be used in HIV+ 
patients who have functional GI tracts. 
Total parenteral nutrition (TPN) should 
not be used unless the prognosis 
warrants aggressive nutritional 
intervention. Some patients with end 
stage AIDS might be better supported 
with IV dextrose and vitamins and 
minerals to meet hydration and basic 
physiological needs without aggressive 
nutritional support1• A key issue in the 
provision of TPN to patients with AIDS 
is the concern about infection. TPN can 
lead to systemic infections, and there 
may be a heightened risk in the AIDS 
patient. 
The efficacy of TPN in the 
restoration of lean body mass HIV+ 
patients is under investigation. Studies 
show variable results on body 
composition, with increased fat stores 
seen in the majority of patients, but 
increased protein mass in only a few. 
I Flaslcerud, J .H. and Ungvarslci , P.J ., HIV/AIDS: A 
Guide to Nursing Care, W.B. Saunders Co, 
Philadelphia, 1992. 
1 McCorlcindale, C., Dybevilc, K., Coulsten AM, et al. 
Journal American Dietetic Association, 1990; 90 . 
• Kotler, D.P. (1991) Biological and Clinical Features 
of HIV Infection In Gastrointestinal and Nutritional 
Manifestation of the Acquired Immunodeficiency 
Syndrome (ed . Kotler, D.P.) New York: Raven Press. 
• Malnutrition in Acquired Immunodeficiency 
Syndrome: Causes and Treatment, Mead-Johnson, 
1994. 
' Watson, Ronald R. (ed .) Nutrition and AIDS, Ann 
Arbor; CRC Press 1994. 
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They concluded that attempts to 
maintain body mass could prolong 
survival in persons with AIDS 1• 
In AIDS patients, the disease 
related abnormalities in immune function 
make it difficult to interpret the effects 
of malnutrition on immune function in 
isolation from disease-related effects. 
However, deficiencies in essential 
nutrients may indeed compound the 
immunodeficiency characteristic of 
AIDS, rendering patients more 
susceptible to infections or exacerbating 
the severity of existing infections. Since 
not all patients with AIDS suffer from 
repeated infections, it is thought that the 
impaired immune system in AIDS 
patients may be better equipped to 
withstand certain environmental 
pathogens in the absence of malnutrition. 
Numerous micronutrient 
deficiencies have been observed in HIV-
infected patients. In one study of the 
prevalence of abnormalities of plasma 
vitamin and trace element concentrations 
in 30 HIV infected patients, one or more 
abnormalities were found in the majority 
of patients. There have been reports of 
low serum zinc, selenium, and vitamin 
812 levels. The prevalence of folate 
deficiency is variable and depends on the 
dietary habits of individual patients. 
Deficiencies of vitamins A, E, 8 6, C, 
choline, and carotenes have also been 
noted4 • 
These numerous micronutrient 
deficiencies may have detrimental effects 
on various organ systems, including the 
immune system, even in otherwise 
healthy individuals . It can thus be 
speculated that the deleterious effects of 
the immune system may be even greater 
in HIV infected persons, who already 
have a defective immune system from 
viral activity alone. 
Some effects of malnutrition on 
immune functions are direct, while 
others are secondary, resulting from 
effects on other organ systems having 
immune regulatory functions or from the 
negative effects on all cellular 
metabolism, including cells of the 
immune system. Virtually all 
components of the immune system may 
be affected by malnutrition, including 
cell-mediated and humoral immunity, the 
complement system, the production of 
cytokines, and phagocytosis1• 
Because of the multifactorial 
nature of malnutrition in HIV disease, 
and because of the wide-ranging effects 
of malnutrition on the immune system, 
early monitoring, detection, and 
intervention regarding the nutritional 
management of HIV infected persons is 
essential. Each nutritional care plan 
should be individualized to meet the 
specific needs of the patient. It is 
imperative that the patient have an active 
role in the plan in an effort to optimize 
commitment and compliance. 
Efforts to improve oral food 
intake are an important first step . These 
include providing nutritional counseling 
and education as soon as HIV disease is 
diagnosed, emphasizing adequate protein 
and calorie intake (high protein I high 
carbohydrate) and encouraging the 
appropriate servings of the four food 
groups . Supplementing the diet with 
multivitamin and mineral preparations 
containing 100 % of the recommended 
daily allowance for all micronutrients is 
also appropriate. Although there is no 
scientific evidence that megadoses of any 
vitamin or mineral will alter the course 
of AIDS, much attention is being paid 
currently to so-called anti-oxidant 
therapies . We encourage careful 
scrutiny of these therapies , as further 
clinical trials are needed to confirm their 
efficacy and identify adverse side 
effects. 
In addition to assuring adequate 
food intake of HIV-positive patients, 
development of rational strategies should 
be a high priority in their over-all care. 
It is imperative to rule out any and all 
causes of wasting, and to treat those 
underlying causes with drug or other 
appropriate therapy, while at the same 
time giving consideration to the best and 
most important nutritional strategies for 
that individual patient at that point in 
time. 
If you have questions or concerns 
regarding HIV and NutriJion, the 
AIDS Consultation Service's 
Nutritional. Constdtant, Pamela 
Perkins is available for questions by 
calling the AIDS lnfonnation Hotline 
at 1-800-871-2701. 
Clinical Strategies in Provision of Nutritional 
Support for Persons with HIV 
I. Assessment of Nutritional Status 
A. Regular chart of weight. 
B. Consider referral to registered dietitian for complete assessment. 
C. Key lab values to follow: albumin, cholesterol, triglycerides, H&H 
II. General Principles of Nutrition for HIV 
A. Encourage high calorie, nutrient dense foods. 
B. Increase number and size of meals. 
C. Use calorie containing condiments and add calorie containing supplements 
as needed. 
D. Encourage daily multivitamin with 100% daily recommended allowances. 
m. Other Strategies to Increase Calorie Intake in Patients with Weight Loss 
A. Rule out opportunistic infection if low CD4 count (MAI, enteric parasites/bacteria) 
B. Rule out depression if low calorie intake. (Refer to arlicle on Depression & HIV) 
C. Consider enteral supplementation 
1. Intact formulas (Protein derived from sodium & calcium caseinate, soy protein 
isolate, such as Ensure, Jevity, or Osmolite HN) 
2. Specific formulas 
Fat malabsorption : (Modified fat such as Lipisorb) 
Elemental: (Free amino acids such as Vivonex, Tolerex) 
D. Consider appetite stimulation 
1. Megasteral accetate Megace (800 mg/d) 
Note high cost and relatively small associated increase in lean body mass. 
2. Dronabinol Marino[ (5 mg/day) 
Note high cost and relatively small associated increase in lean body mass. 
Common Medications Used in the Treatment of HIV 
That May Affect Appetite and Nutrition 
Medication GI Side Affects Interventions 
AZT nausea, diarrhea Take with food 
(Common with high dosages Symptoms often improve 
early in treatment) with time 
Consider decreasing dosage 
if persistent symptoms 
DDI occasional nausea, diarrhea For minor GI symptoms, 
pancreatitis (rare) can consider switching 
between tablet and powder 
formulations. 
DDC Nausea (occasional) Take with food. 
Mouth ulcers (rare) 
D4T Nausea (uncommon) Take with food. 
Bactrim Nausea, diarrhea Consider change from qd to 
Stomatitis (rare) 3x/week dose for 
Glossitis (rare) pneumocystis prophylaxis 




200 mg/ q week 
Rifabutin Nausea, anorexia (rare) Take with food. 
Consider split dose (ie. 
150mg bid) for 
mycobacterium avium 
prophylaxis. 
The AIDS Consultation Service's AIDS Infonnation Hotline Phannacist 
is available Monday - Friday 9:00 am - 4:00 pm 
to answer any questions you may have regarding medications 
used to treat HIV/AIDS and their side affects. 
1-800-871-2701 
Treatment of Depression In HIV 
In the evaluation of the patient with poor nutrition, depression should be considered. Depressive symptoms 
are not uncommon among HIV I AIDS patients. Depression may be initially manifested by weight loss and fatigue, 
which are common complaints of HIV disease. The challenge is to tease out symptoms that are an appropriate 
reaction to the disease from those that are due to HIV itself, and to determine whether or not a major depressive 
disorder is present. Some of the symptoms to consider are decreased mood, general anhedonia, significant weight 
loss or gain, insomnia or hypersomnia, motor agitation or retardation, fatigue, feelings of worthlessness, lack of 
concentration, recurrent thoughts of death, and over reaction to health issues. While considering these, it is 
beneficial to keep in mind that this patient may have had a predisposition to depression before the HIV I AIDS 
diagnosis, and to obtain careful history of previous mood disturbances, etc. 
The following charts from AIDS Clinical Care provide a suggested approach to the treatment of depression 
in patients with HIV. 
I. Depression Treatment 







failed other treatments 



























failure from side effects 
(switch call of antidepressants) 
~--------------------------------+ 
failure after good trial 
,!. 
lithium augmentation (risk/benefit) 
,!. 
next drug 
Charts reprinted by permission of AIDS Clinical Care 1440 Main Street, 
Waltham, MA 02154, Vol.6, Number 8, Glemi J. Treisman, M.D., Mental 
Health Care of HIV Patients Part I: Managing Psychiatric Disease, pp 63-66, 
1994. 
m. Failed Drug Trial for Depression 
,!. 
principles: choose by side effects, case profile, 






serotonin specific reuptake inhib. 
monoamine oxidase inhibitor 





sleep deprivat. augmentation 
phototherapy 
electroconvulsive therapy 
On-Going Clinical Trials at AIDS Consultation 
Service 
Delavirdine In Combination with 
AZT or DD/ 
Maine Medical Center's AIDS Consultation Service is 
enrolling in these two clinical trials or a new anti-retroviral 
drug, delavirdine, which is used in combination with AZT or 
DDI. Patient enroUment is expected to continue for 6 months. 
All antiviral medications, study related laboratory costs, and 
research clinical visits are provided at no cost to the patient. 
Physicians interested in referring patients for inclusion in this 
2 year study should call the AIDS Consultation Service at 
1-800-871-2701. 
Open Label, Triple Antiviral 
Combination Drug Study 
(AZT, DD/ or DDC, plus delavirdine) 
Patients with progression of ~e in the 2 studies 
noted above may, after 6 months on double combination 
therapy, enroll in this open label triple combination therapy 
trial. Antiretroviral medications, laboratory, and research 
visits will be free to the patient as in the other 2 delavirdine 
studies. The open label trial will continue ror 2 years. 
World AIDS Cases 2,500,000* 
US AIDS Cases 361,509 
US AIDS Deaths 220,871 
Total US cases and deaths reponed through 12131/93 
Maine AIDS Cases 530 
Maine AIDS Deaths 279 
Total Maine cases and deaths reponed through 06/30/94 
*Estimated 
Upcoming HIV/AIDS Education 
September 6, 1994 
8:00 - 9:00 am 
September 23, 1994 
9:00 - 10:00 am 
September 23, 1994 
2:30 - 3:30 pm 
September 26 & 27, 1994 
September 27, 1994 
October 6, 7, 8, 1994 
October 16, 1994 
November 2, 1994 
November 28, 1994 
8:00 - 10:00 am 
Outpatient Management of Grand Rounds ... Family Practice Grand Rounds at Maine Medical Center 
Presented by - Robert P. Smith, M.D. (207)871-2099 
Pain Management in the Cancer and AIDS Patients ... NE Osteopathic Association (207)474-2357 
Presented by - Owen Pickus, D.0. 
HIV/AIDS Update for Physicians ...••• NE Osteopathic Association (207)474-2357 
Presented by - David Loughran, 0.0. 
HIV 101 & Care of PW A's at Home ... Hospice of Maine 
Presented by - Sandra T. Putnam, RN, MSN, FNP (207)871-2099 
Update from the International Conference on AIDS: Yokohama, Japan .. . Sponsored by New Eng. AIDS 
Ed. and Training Center 
HIV/AIDS in the Dental Setting ... Sponsored by New Eng. AIDS Ed. & Training Ctr - Maine 
at the Comfort Inn, Augusta, Me. 
Women's Health Care Issues Across the Life Span ... Sponsored by University of Southern Maine at the 
Ramada Inn, Portland, Maine 
Community Advocacy & Family Connections Contemporary Practice with HlVIAIDS ... Sponsored by 
USM and ACS at Holiday Inn by the Bay, Portland, Me. 
Psychosocial Issues & HIV ... University of New England, Biddeford, Maine 
Presented by - Jane K. O'Rourke, LCSW (207)871-2099 
If you are providing an HIV/AIDS related educational session, please let us know at (207)871-2099 
Maine Medical Center 
AIDS Consultation Service 
22 Bramhall Street 
Portland, Maine 04102 
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